BNTXUS

Premarket

Back To Top

Last Updated: Aug 31, 2021 7:19 a.m. EDT Delayed quote

$ 340.30

-4.70 -1.36%

Before Hours Volume: 15.51K

Close Chg Chg %
$345.00 -13.48 -3.76%
  • Open $351.00
  • Day Range 342.79 - 360.33
  • 52 Week Range 54.10 - 464.00
  • Market Cap $86.94B
  • Shares Outstanding 238.17M
  • Public Float 240.92M
  • Beta 0.68
  • Rev. per Employee $283.28K
  • P/E Ratio 18.11
  • EPS $19.05
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 2.07M 08/13/21
  • % of Float Shorted 0.86%
  • Average Volume 3.97M
5 Day
  • -6.30%
1 Month
  • -1.94%
3 Month
  • 67.36%
YTD
  • 323.21%
1 Year
  • 496.78%
  • MarketWatch
  • Dow Jones
  • Other News
  • Press Releases

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The companys portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.